282 53

Full metadata record

DC FieldValueLanguage
dc.contributor.author이영호-
dc.date.accessioned2022-10-27T05:06:56Z-
dc.date.available2022-10-27T05:06:56Z-
dc.date.issued2021-02-
dc.identifier.citationCHILDREN-BASEL, v. 8, no. 2, article no. 109, page. 1-12en_US
dc.identifier.issn2227-9067en_US
dc.identifier.urihttps://www.mdpi.com/2227-9067/8/2/109en_US
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/175882-
dc.description.abstractAcute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved complete remission (CR). The 5-year overall survival (OS) and event-free survival (EFS) rates were 58.8 +/- 4.2% and 49.8 +/- 4.2%, respectively. Based on the response to induction therapy, the 5-year OS was 66.9 +/- 5.7% in patients with CR (p ˂ 0.001). Ninety-nine patients with CR after induction therapy were examined, and their 5-year OS and EFS were 66.4 +/- 4.9% and 56.3 +/- 5.1%, respectively. The 5-year OS rates according to treatment were 59.9 +/- 7.4% in the chemotherapy group and 72.3 +/- 6.3% in the hematopoietic stem cell transplantation (HSCT) group (p = 0.089). The EFS was 50.1 +/- 7.4% in the chemotherapy group and 61.7 +/- 6.9% in the HSCT group (p = 0.098). OS and EFS according to cytogenetics were insignificant. Our findings confirmed that the response to induction treatment was important for survival and HSCT had no significant survival benefits compared with those of chemotherapy. Moreover, many early induction deaths under the age of 2 years were observed.en_US
dc.description.sponsorshipThis work was supported by the 2020 Yeungnam University Research Grant (220A480014).en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.subjectacute myeloid leukemia; hematopoietic stem cell transplantation; prognosis; pediatric; childhood; Koreaen_US
dc.titleTreatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology-Oncology (SAYPH)en_US
dc.typeArticleen_US
dc.relation.no2-
dc.relation.volume8-
dc.identifier.doi10.3390/children8020109en_US
dc.relation.page1-12-
dc.relation.journalCHILDREN-BASEL-
dc.contributor.googleauthorLee, Jae Min-
dc.contributor.googleauthorYang, Eu Jeen-
dc.contributor.googleauthorPark, Kyung Mi-
dc.contributor.googleauthorLee, Young-Ho-
dc.contributor.googleauthorChueh, Heewon-
dc.contributor.googleauthorHah, Jeong Ok-
dc.contributor.googleauthorPark, Ji Kyoung-
dc.contributor.googleauthorLim, Jae Young-
dc.contributor.googleauthorPark, Eun Sil-
dc.contributor.googleauthorPark, Sang Kyu-
dc.relation.code2021007021-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidcord-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE